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In vivo gene transfer into rat arterial walls 
with novel adeno-associated virus vectors 
Thomas E. Arnold, MD, Dmitr i  Gnatenko, PhD, and Wadie F. Bahou, MD, 
Stony Brook, N.Y. 
Purpose: We studied the ability of recombinant adeno-associated virus (rAAV) vectors to 
achieve gene transfer in vivo to intact rat carotid arteries. 
Methods: Isolated segments of uninjttred rat carotid arteries were incubated with (1) 
rAAV vectors that expressed a f~-galactosidase gene, (2) a related vector with no pro- 
moter, or (3) a normal saline solution. Gene transfer was evaluated with in situ polymer- 
ase chain reaction (PCR). Transgene expression was assessed at intervals that ranged from 
24 hours to 2 months by measurement of ~-galactosidase activity and protein mass in 
tissue extracts with fluorometric and enzyme-linked immunosorbent assays, respectively. 
Dose dependence ofexpression was determined for virus concentrations that ranged from 
5 x 104 to 5 x 10 s infectious units (iu)/ml. 
Results: Light microscopic analysis of in situ PCR-stained histologic sections of trans- 
duced vessel walls showed approximately 90% of intimal and medial cell nuclei contained 
the [3-galactosidase g ne, compared with none in control arteries. In vivo [3-galactosidase 
expression was (1) highest 24 hours after gene transfer, (2) elevated for I month, and (3) 
dose responsive. 
Conclusions: rAAV vectors can mediate focal gene transfer into the intact rat carotid 
artery with detectable l vels of transgene xpression for 1 month and are potentially 
useful agents for in vivo gene transfer into intact arteries. (J Vasc Surg 1997;25:347-55.) 
The feasibility of gene transfer as an approach to 
treat vascular disease has been established. Gene 
therapy strategies in living animals for inhibiting ar- 
terial intimal hyperplasia, ~ 2 delaying vein graft ath- 
erosclerosis, 3,4 and preventing thrombosis, ,6 as well 
as for promoting angiogenesis in humans, 7 have re- 
cently been reported. However, the fundamental is- 
sue of  selecting the best agent for arterial gene deliv- 
ery remains unresolved. The vehicles currently used 
are either viral or nonviral. Infectious recombinant 
viral vectors, because of natural host-virus affinity, 
may be the most efficient agents. 8 
Adeno-associated virus (AAV) is a mammalian 
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transduction vector with characteristics that make it 
promising as an agent for human gene therapy, in- 
cluding (1) the ability to infect a broad range of 
human cell types in culture with high efficiency and 
to latently infect nondividing cells with stable and 
efficient integration of viral DNA, 8,9 (2) the tendency 
for site-specific integration into a distinct 7-Kb re- 
gion of human chromosome 19, l°,ll (3) the expres- 
sion of a minimal number of viral antigens to induce 
a host immune response, 9 and (4) the lack of associ- 
ated symptoms or disease subsequent to human in- 
fection, although 80% of adults are seropositive for 
antibodies against AAV. 9 
Recombinant AAV (rAAV) vectors have potential 
advantages over retroviral vectors, including physical 
stability, which allows concentration to titers of 
101°, z2 and the ability to mediate gene transfer and 
expression in vitro into nondividing cells. 13,14 Mso, 
in contrast o adenoviral vectors, rAAV vectors lack 
cytopathogenicity. 15~17 
Because of the potential advantages of rAAV vec- 
tors, we initiated studies to determine the feasibility 
of in vivo arterial gene transfer with these agents. 
Previous work in our laboratory showed tropism of 
wild-type AAV (wtAAV) for cultured primary human 
umbilical vein endothelial cells (HUVECs), as well as 
for rat arterial intimal and smooth muscle cells in 
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vivo. In addition, we used rAAV vectors encoding 
the [3-galactosidase gent (lacZ) to transduce HUVECs 
in vitro, with [3-galactosidase expression detectable by 
histochemical staining with XGAL in 5% to 8% of cells 
(unpublished data from Dmitri Gnatenko, PhD, SUNg 
at Stony Brook). 
The focus of this study was to establish the ability 
of rAAV vectors that contained lacZ to transduce 
arterial wall cells by temporary direct exposure in vivo 
in an intact rat carotid artery model. The purpose of 
the study was to determine (1) the feasibility of in 
vivo arterial rAAV gene transfer, (2) the level and 
duration of recombinant gene expression conse- 
quent o gene transfer, and (3) the dose dependence 
of transgene expression. 
MATERIAL AND METHODS 
Construction of rAAV vectors. Three plasmids 
were used to construct rAAV stocks for this study. 
The plasmid pTRCola(I)13geo (provided by Dr. A. 
D. Miller, Seattle, Wash.) contained the murine col- 
lagen c¢(I) promoter upstream to the [3-galactosi- 
dase-NEO fusion gene ([3geo) and the polyadenyla- 
tion signal of SV40 early genes (pAE) , flanked by 
AAV inverted terminal repeats (TRs). Plasmids 
pTRCMV[3 and pTRI3 were generated by standard 
techniques with use of the backbone plasmid 
pBR322, as previously described. 1s,19 pTRCMVI3 
contained the cytomegalovirus (CMV) immediate- 
early promoter and enhancer upstream to the late 
gene 16S/19S splice donor/splice acceptor signal of 
SV40 (SD/SA), upstream to lacZ, the polyadenyla- 
tion signal of SV40 late genes (pAl) , and pA z in 
order, flanked by TRs. pTR~ contained SD/SA up- 
stream to lacZ, pAi, and pAE in order, flanked by 
TRs, and thus contained no promoter. 
rAAV viral stocks were prepared and titered by 
use of established procedures? 9-21 Human 293 
(adenovirus type-5 transformed embryonic kid- 
ney) cells were plated at a density of 5 × 106 
cells/100 mm 2 dish, and 5 Ixg of individual 
cesium-banded plasmids [pTRCola(I)t3geo, 
pTRCMVI3, or pTRI3] were used to transfect 293 
cells with use of the calcium phosphate precipita- 
tion method of Chen and Okayama. 2°Cotransfec- 
tions were completed at 39.5° C in 3% carbon 
dioxide with 15 Ixg of the complimenting plasmid 
pIM45--which is defective for packaging but sup- 
plies the wtAAV gene products in trans--and 2 × 
107 plaque-forming units (pfu) of adenovirus 
ts149 (a temperature-sensitive strain that is non- 
permissive at more than 39 ° C). Approximately 48 
hours after initial transfections, lysates were pre- 
pared by freezing and thawing, contaminating ad- 
enovirus was inactivated by 55 ° C incubation for 
60 minutes, and cellular debris was pelleted by 
centrifugation at 2000 rpm for 10 minutes. 
rAAV titers determined by replication center as- 
say, as described previously. 22 In brief, in microdilu- 
tion plates, approximately 2.5 × 104 293 cells were 
infected with rAAV stocks constructed with the 
rAAV plasmids pTRCole~(I)[3geo, pTRCMV[3, or 
pTR[3. Serial dilutions of the rAAV, adenovirus 
[multiplicity of infection (MOI), 20 pfu/cell] and 
wtAAV (MOI 2), were added to each well. A control 
well was infected with adenovirus alone (no rAAV or 
wtAAV), and adenovirus contamination was ex- 
cluded by replication center assays in the absence of 
exogenous adenovirus. After 30 hours, cells were 
removed using trypsin, and they were resuspended 
and trapped on nitrocellulose filters under suction. 
Filters were then hybridized to [3-galactosidase g ne 
(lacZ) [32p]DNA to detect he recombinant gene. 
The total number of dots on autoradiographs of each 
filter disk was estimated to determine the relative 
titers of individual rAAV stocks (data not shown). 
Titers were calculated as described by Hermonat and 
Muzyczka 19 and expressed as infectious units per 
milliliter (iu/ml). 
Stocks were evaluated for evidence of contami- 
nating wtAAV in experiments completed in parallel 
with titering. One microliter of the rAAV and adeno- 
virus (MOI, 20 pfu/cell) was added to each well of 
293 cells, as described for titering. Filters were simi- 
larly prepared but were then hybridized to wild-type 
[32p]DNA to detect possible contamination. No ev- 
idence of wtAAV contamination existed on autora- 
diographs of the filter disks, with an estimated sensi- 
tivity of 100 iu/ml (data not shown). 
Stocks generated included (1) rAAV/Col, driven 
by the murine collagen a(I) promoter; titer = 5.0 × 
10 s iu/ml, (2) rAAV/CMV, driven by the CMV 
immediate-early promoter and enhancer; titer = 
4.5 × 10 s iu/ml, and (3) rAAV/pTR[3, the control 
vector with no promoter; titer = 3.0 × 105 iu/ml. 
AvlLacZ4, a recombinant replication-deficient ade- 
novirus encoding lacZ, was constructed asdescribed 
previously 2sand used as a positive control, titer = 
3 × 10 l° pfu/ml; (provided by Dr. B. Trapnell, 
Genetic Therapy Inc., Gaithersburg, Md.). 
To select the vector with the highest level of 
expression, HUVECs were transfected in vitro with 
individual rAAV constructs, and [3-galactosidase ex-
pression in these cells was evaluated with quantitative 
[3-galactosidase activity 4-methylumbelliferyl-[g-gal- 
actoside (MUG) assays, rAAV/Col and rAAV/CMV 
showed protein expression, with [3-galactosidase ac-
tivity approximately 400% and 200% above control, 
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respectively (unpublished ata from Dmitri Gna- 
tenko, PhD, SUNY at Stony Brook, April 1995). 
These observations supported the decision to pro- 
ceed with in vivo studies, with use of rAAV/Col 
primarily, and to study rAAV/CMV at the 24-hour 
interval only. 
Animals. All animal procedures complied with 
the "Principles of Laboratory Animal Care" (from 
the National Society for Medical Research) and the 
Guide for the Care and Use of Laboratory Animals 
(National Institutes of Health publication No. 86- 
23, revised 1985) and were approved by the Institu- 
tional Animal Care and Use Committee of the SUNY 
at Stony Brook. Adult male Sprague-Dawley rats 
(Taconic Farms, Inc., Germantown, N.Y.) that 
weighed 450 to 650 gm were used. Rats were anes- 
thetized with intramuscular injections of ketamine 
(83 mg/kg, Fort Dodge Laboratories, Inc., Fort 
Dodge, Iowa) and xylazine (8.3 mg/kg, Miles Inc., 
Shawnee Mission, Kan.). After surgery, rats were 
returned to their cages and allowed water ad libitum. 
In vivo gene delivery. The right carotid artery 
was surgically exposed, and a segment of common 
carotid artery ~ 1 cm long was isolated between vas- 
cular clamps. An arteriotomy was performed in the 
external carotid artery. A 24-gauge plastic catheter 
was introduced through the arteriotomy, and the 
isolated vessel segment was flushed with normal sa- 
line solution before instillation of 50 I*1 of either 
vector or control solution. Intraluminal pressures, 
measured with a standard pressure transducer during 
several vector infusions under usual conditions, 
ranged from 150 to 190 mm Hg (data not shown). 
rAAV stocks were thawed and maintained on wet ice 
until use. All stocks were used within 2 hours of 
thawing. After 30 minutes of incubation, the instilled 
solution was withdrawn, the external carotid artery 
was ligated, and blood flow through the common 
and internal carotid arteries was reestablished. 
At varying time intervals after gene transfer, ani- 
mals were reanesthetized, and the right common 
carotid artery was harvested. In addition, the left 
carotid artery was dissected from each animal nd 
processed in the same manner as the right artery to 
serve as a paired control. The anesthetized animal 
was then killed by ether inhalation. At the time the 
animal was killed, all common carotid arteries were 
patent. 
Detection of  transgene (LacZ) delivery with 
in situ DNA polymerase chain reaction (PCR). 
Artery segments for DNA in situ PCRwere removed, 
washed in phosphate buffered saline solution, fixed in 
10% neutral buffered formalin, and then frozen in 
OCT (Miles, Inc, Elkhart, N.Y.) by immersion in 
liquid nitrogen. Cryosecfions of 4 ~m were then 
placed on silane-coated slides and evaluated for viral 
incorporation with [3-galactosidase-specific oligonu- 
cleotide primers (5'-AAG CAG CGT TGT TGC 
AGT GCA-3' [base pairs (bp) 2456-2476]; 5'-ATA 
TTC AGC CAT GTG CCT TCT-3' [bp 2957- 
2937]), and DNA in situ PCR. 24 In brief, sections 
were digested with pepsin (2 mg/ml) for 30 minutes 
at 25°C and washed in diethyl pyrocarbonate- 
treated water. Products were then amplified with 
digoxigenin- 11-dUTP and "hot-start" PCR to in- 
hint nonspecific mispriming. Segments from paired 
left arteries were used as negative controls. For posi- 
tive controls, arterial segments were evaluated with 
primers pecific for rat [3-actin (5'-CAG GCT GTG 
TTG TCC CTG TAT-3' [bp 913-934]; 5'-TTC 
ATG GAT GCC ACA GGA TTC-3' [bp 1399- 
1420]). Slides were then washed in xylene for 5 
minutes, rinsed in 100% ethanol, and vacuum-dried 
before immunodetection with the alkaline phospha- 
tase-conjugated anti-digoxigenin a tibody (diluted 
1:200 at 25 ° C for 30 minutes). Detection was com- 
pleted with the substrates nitroblue tetrazolium and 
BCIP for 10 minutes. Sections were counterstained 
with nuclear fast red and examined by light micros- 
copy for the presence of blue-black nuclear amplifi- 
cation and staining, indicative of lacZ transfer. Rep- 
resentative s ctions of arterial segments were stained 
with hematoxylin and eosin to evaluate for the pres- 
ence of intimal and medial cell necrosis and acute 
inflammatory cell infiltration. 
Estimation of  transduction frequency. To es- 
timate the transduction frequency in the vessel wall, 
three PCR-stained histologic sections from each of 
two arteries (n = 6) transduced with rAAV/Col or 
rAAV/CMV were analyzed vdth light microscopy. 
An estimate of the number of cell nuclei that showed 
lacZ transfer per section was obtained, as well as the 
total number of nuclei per section. The percentage of
vessel wall cells transduced was calculated. 
Measurement of  recombinant [g-galactosidase 
activity and antigen. [3-Galactosidase expression 
was evaluated indetergent extracts of excised arteries 
with two quantitative methods that measured (1) 
activity with use of MUG assays and (2) protein mass 
(antigen) with use of an enzyme-linked immunosor- 
bent assay (ELISA) kit (5 Prime 3 Prime, Inc., Boul- 
der, Colo.). 
Arterial segments for MUG analysis were minced 
in lysis buffer that contained 0.2% Triton X-100 and 
Z-buffer (60 mmol/L sodium phosphate dibasic, 
40 mmol/L sodium phosphate monobasic, 10 
mmol/L potassium chloride, and 1 mmol/L magne- 
sium sulfate, pH 7.0). Tissue debris was cleared by 
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centrifugation at14,000g for 6 minutes. Fifty micro- 
liters of tissue extract was added to 650 Ixl of Z- 
buffer. The reaction was started by addition of 200 ~1 
of 3 mmol /L  MUG in Z-buffer. The reaction was 
monitored for 1 hour with use of a luminescence 
spectrometer (Perking-Elmer, Norwalk, Conn.), 
with excitation at 350 nm and emission at 450 nm. 
~-Galactosidase activity was determined on the basis 
of the linear portions of ldnetic curves generated by 
use of purified Escherichia coli [3-galactosidase (Sigma 
Chemical Co., St. Louis, Mo.), with specific activity 
ranging from 1.5 to 200 IxU. Assay samples with 
light emission below that generated by the 1.5 IxU 
standard were read as "undetectable." 
The sensitivity of  the MUG assay, along with 
inherent variation in the kinetic curves generated for 
assays completed on different days, led to variation in 
the individual standard curves generated for the ac- 
tivity assays. For this reason, variability of calculated 
activity occurred when animals assayed at different 
times were compared; for example, activity for the 
endogenous rat 13-galactosidase in unoperated con- 
trol arteries. In all cases, specimens from individual 
rats were assayed with a single standard. That is, 
although values for the right and left arteries varied 
according to which standard was applied because of 
the linearity properties of the standard, the right/left 
ratio remained constant. Therefore the ratio of re- 
combinant protein activity in the transduced (right) 
artery versus the activity in the paired control (left) 
artery of  each individual rat accurately reflected the 
changing levels of  [3-galactosidase activity over time 
or subsequent to varying vector concentrations. For 
this reason, this ratio (i.e., [3-galactosidase activity of 
right artery/J3-galactosidase ctivity of left artery) 
was calculated for each individual animal. The mean 
of these ratios was calculated for all animals is each 
experiment, and the mean of the ratios, rather than 
the absolute activity values, was used for comparing 
results between experiments. 
Tissue extracts of artery segments for ELISA were 
prepared as described previously, 2s except hat the 
adventitia was left intact on the specimens. ELISA 
assays gave a linear response to standard J3-galactosi- 
dase concentrations between 100 to 2000 pg/mg of 
total protein. Total protein concentrations in vessel 
extracts were made with use of a standard protein 
determination kit (Pierce Chemical Co., Rockford, 
Ill.), with bovine serum albumin as a standard. 
Evaluation o f  durat ion of  recombinant I~-ga- 
lactosidase expression. Carotid arteries of 17 rats 
were used to assess J3-galactosidase expression 24 
hours after instillation fvector or control solutions, 
including (1) rAAV/Col (n = 10), (2) rAAV/CMV 
(n = 4), and (3) rAAV/pTRI3, the vector without a 
promoter, as a negative control (n = 3). One rAAV/ 
Col rat underwent simultaneous instillation of nor- 
mal saline solution into the contralateral ( eft) ca- 
rotid artery to serve as a surgical control. AvlLacZ4, 
the adenoviral vector, was instilled in two rats. 
AvlLacZ4-instilled arteries were harvested at 72 
hours, which was the interval used with this vector in 
previous studies that showed significant ransgene 
expression. 15,2s Twenty-five additional rats were in- 
cluded in a time-course study with use of rAAV/Col 
as the vector. Arteries were harvested at varying in- 
tervals after in vivo gene transfer, as follows: 96 hours 
(n = 4), 1 week (n = 8), 2 weeks (n = 4), 1 month 
(n = 5), and 2 months (n = 4). 
[3-Galactosidase expression was evaluated in indi- 
vidual artery segments at each time interval with 
MUG assays and at 24 hours (n = 4) and 1 week 
(n = 3) with ELISA assays. DNA in situ PCR was 
used to assess the number and distribution of vessel 
wall cell nuclei that contained the lacZ gene at 24 
hours, 1 week, and 2 months. 
At intervals when vessels were evaluated by more 
than one type of  assay, one vessel was divided into 
two segments and used for two assays, if possible, 
to minimize the number of  animals required. (For 
example, when gene transfer was assessed with 
PCR and gene expression was measured with the 
MUG assay at 2 months after gene transfer). For 
this reason, the total sample size (n) for assays and 
stains exceeds the number of  rats used in the study. 
Evaluation of  effect o f  viral titer on transdnc- 
t ion and expression. To evaluate the effect of viral 
titer, eight additional rats were included in a dose- 
dependence study. Arteries were infused with 50 
~1 of  a 1:1 dilution of  rAAV/Col stock (final titer, 
2.5 × l0 s iu/ml;  n = 4) or a 1:10 dilution (final 
titer, 5 × i04 iu/ml;  n = 4) for comparison with 
arteries infused with undiluted rAAV/col stock 
(titer, 5 X 105 iu/ml;  n = 6). The diluent was 
normal saline solution. ~-Galactosidase expression 
was evaluated in individual segments with MUG 
assays. 
Statistics. For each group of  vessels or animals 
that received the same treatment in individual ex- 
periments, mean values were calculated from the 
values for individual vessels or animals constituting 
a group; for example, [3-galactosidase activity lev- 
els, J3-galactosidase antigen levels, and ratios of 
activity level in transduced versus control arteries. 
The Sign test was used to evaluate the significance 
of  differences between transduced and control ar- 
teries; differences were considered to be significant 
at p < 0.05. 
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RESULTS 
In vivo gene delivery and estimation o f  trans- 
duct ion frequency. Arteries were incubated with 
rAAV/Col (n = 6), rAAV/CMV (n = 4) or normal 
saline solution (n = 1) and harvested at 24 hours 
after gene delivery. For transduction frequency esti- 
mates, the number of PCR-stained cell nuclei per 
histologic section of whole vessel was counted for 
each vector, as well as the total number of cell nuclei 
per histologic section, and the percentage of positive 
cells was calculated. Results were expressed as the 
mean values + SEM (n = 6 sections from two ani- 
mals for each vector). With use of rAAV/Col, the 
total number of cell nuclei was 82 + 6 per section, 
with 91% + 1% of cells positive (range, 85.9% to 
94%). With use of  rAAV/CMV, the total number of 
cell nuclei was 84 + 6 per section, with 89% + 1% of 
cells positive (range, 84.6% to 92.2%). Thus in situ 
PCR amplification and staining of intimal and 
smooth muscle cell nuclei provided evidence for the 
presence of  the foreign lacZ gene, compared to none 
in normal saline solution-instilled arteries and in 
unoperated control arteries. No evidence of signifi- 
cant intimal or medial cell loss or acute inflammatory 
cell infiltrates was noted after light microscopic anal- 
ysis of sections of the infected vessel wall stained with 
hematoxylin and eosin (Fig. 1, A through F). 
Level and durat ion o f  recombinant [3-galacto- 
sidase expression. The level of [3-galactosidase ac- 
tivity was assayed in individual vessel extracts at 24 
hours after gene transfer from vessels instilled with 
rAAV/Col (n = 6), rAAV/CMV (n = 4), and 
rAAV/pTR[3 (n = 3). Vessels instilled with 
AvlLacZ4 (n = 2) were harvested at 72 hours. 
Activity was expressed in mean microunits per milli- 
gram of total protein (Fig. 2). At 24 hours, the 
rAAV/Col vector mediated significant protein ex- 
pression (p = 0.015), whereas the rAAV/CMV and 
rAAV/pTR[3 vectors did not. 
Although transduction with the AvlLacZ4 vec- 
tor resulted in [3-galactosidase activity more than 
18-fold higher than in paired unoperated arteries the 
sample size was too small to allow statistical analysis. 
Because ahigh level of expression has been reported 
previously with use of this high-titer adenoviral vec- 
tor, 23 our results suggest hat the MUG assay accu- 
rately reflects [3-galactosidase activity. 
To assess the duration of expression, 13-galactosi- 
dase activity was assayed in vessel extracts of arteries 
instilled with rAAV/Col at varying intervals that 
ranged from 96 hours to 2 months after gene trans- 
fer. The ratio of  [3-galactosidase activity in the trans- 
duced to the paired control vessel was calculated at 
each interval for each individual animal (data not 
shown), and the mean of these ratios was calculated 
and is indicated for each group (Fig. 2). Transgene 
expression decreased to a low level at 96 hours and 
remained etectable for 1 month after gene transfer 
(p = 0.03). 
The quantity of ~3-galactosidase antigen was de- 
termined in artery extracts at 24 hours (n = 4) and 1 
week (n = 3), and expressed in picograms per milli- 
gram of total protein (Fig. 3). Because the ELISA 
antigen assay is specific for bacterial [3-galactosidase, 
any difference in antigen quantities must result from 
transgene expression. At 24 hours, the absolute value 
of the antigen levels in the transduced vessels ex- 
ceeded those for control vessels. The values were not 
significantly different because of the small sample 
size, although a statistical trend was shown (p = 
0.06). 
DNA in situ PCR of representative segments at 1 
week and 2 months after gene transfer showed that 
the percentage of cells that contained the transgene 
decreased over time. Two months after gene transfer, 
the nuclei of cells near the luminal surface contained 
lacZ (Fig. 1, G and H). 
Effect o f  viral titer on transduction and ex- 
pression. The level of [3-galactosidase activity was 
assayed in vessel extracts of arteries instilled with 
rAAV/Col at titers that ranged from 5 × 10 4 iu/ml  
to 5 X 10 s iu/ml  (Fig. 3). Transgene xpression 
decreased in a dose-dependent fashion in this 
range of  vector concentrations, although [3-galac- 
tosidase activity ratios subsequent to transduction 
with either diluted vector solution were essentially 
identical to those of the rAAV/pTR[3 control vec- 
tor. Thus transduction with use of  any dilution of  
the vector stocks resulted in loss of  detectable 
levels of  expression. 
DISCUSSION 
In this study, we show in situ PCR evidence that, 
in an uninjured rat artery, AAV vectors driven by two 
distinct promoters can mediate in vivo gene transfer 
to a high percentage of vessel wall cells, despite an 
intact endothelial cell layer. In addition, gene trans- 
fer with use of rAAV/Col, a vector driven by the 
murine collagen c~(I) promoter, is accompanied by 
expression of recombinant protein, detectable by ac- 
tivity and antigen assays of vessel extracts. 
In contrast, gene transfer with the vector driven 
by the CMV immediate-early promoter and en- 
hancer (rAAV/CMV) did not result in detectable 
levels of recombinant protein expression i the inter- 
val examined. Thus successful gene transfer, al- 
though demonstrable by in situ PCR, does not 
uniformly result in significant ranscription and 
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Fig. 1. Microscopic views of sections from rat carotid arteries (original magnification x40). 
All vessels were stained by DNA in situ polymcrasc chain reaction (PCR) to detect he lacZ 
genc, except for panels E and F. Lu indicates the vessel lumen. EC and SMCindicate ndothelial 
cell and smooth muscle cell, respectively. A through D, Show vessels harvested 24 hours after 
instillation of the solution i dicated to the left of each photomicrograph. A and B, Show arteries 
transduced with ndividual recombinant adeno-associated virus (rAAV) vector solutions. Dark 
blue staining of cell nuclei provides evidence for the presence of the lacZ gene. C, Shows an 
artery instilled with normal saline solution. D, Shows an artery that has not been operated on. In 
panels C and D, no blue staining ispresent (nuclear fast red stain). E, Shows a transduced artery 
stained by DNA in situ PCR to detect endogenous rat ~-actin, to serve as a positive control. F, 
Shows an artery transduced with rAAV/Col and stained with hematoxylin and eosin stain. No 
significant cell loss or inflammatory infiltrates are present. G and H, Show DNA in situ PCR of 
arteries 1 week and 2 months after gene transfer with rAAV/Col, respectively. The percentage 
of cell nuclei that contain the lacZ gene decreases with time. At 2 months, lacZ is present in 
nuclei near the vessel lumen (nuclear fast red stain). 
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Fig. 2. Graph showing the level of [3-galactosidase expression at the interval indicated after in 
vivo gene transfer. The vector instilled is indicated to the left of each pair of bars. Bars with plus 
signs (Jr) represent arteries instilled with a vector solution; bars with circles (0) represent paired 
tmoperated control arteries. Activity s expressed as microunits per milligram of total protein in the 
tissue extract. Bars indicate the mean [3-galactosidase activity n each group. Each data point 
represents a single vessel. For ach group, r represents the mean of the ratios that compare activity in 
the instilled versus the paired unoperated artery for each individual animal in that group (see text). 
Where p values are absent, the sample size (n) was toosmall to allow statistical analysis. 
translation of the foreign gene, as emphasized by 
Halbert et al. 2s 
Although the level of  protein expression obtained 
with rAAV vectors was 1000-fold less than the level 
reported with adenoviral vectors (i.e., picograms ver- 
sus nanograms per milligrams of total protein), the 
titers of  rAAV vectors used in this study were 
100,000-fold lower (10 s iu/ml)  than the titers of the 
adenoviral vectors (101° pfu/ml)  used in the previ- 
ous experiments. ~5,2a Transduction with more con- 
centrated rAAV stocks may result in translation of 
higher levels of protein. 
Expression of recombinant protein continues at 
low levels for 1 month after rAAV-mediated gene 
transfer. The mean ratio of activity in the transduced 
versus control vessels is highest (more than seven- 
fold) at 24 hours, decreases by 96 hours (3.4-fold), 
and remains essentially constant at a low level for 1 
month. In comparison, expression after adenoviral 
transduction i  an injured artery model persisted at 
high levels for 7 days, then declined to a low level, 
and remained etectable for 42 days. 2s Whether or 
not long-term expression fro)n recombinant AAV 
vectors is related to stable integration into the ceil 
genome remains to be determined. 
In situ PCR 1 week and 2 months after transduc- 
tion show that, over the course of the study, the 
transgene persists in endothelial cells and in the 
smooth muscle cells nearest to the vessel lumen, 
whereas it diminishes in the smooth muscles cells 
farther from the lumen. We hypothesize that the cells 
nearest o the arterial lumen may initially receive 
higher copy numbers of the transgene as a result of  
the luminal delivery of the vectors. The quiescent 
nature of endothelial ceils, in contrast to the higher 
turnover ate of smooth muscle cells, may also con- 
tribute to the observed persistence of the transgene 
in the endothelium for up to 2 months. 
Arterial transduction with high-titer adenoviral 
agents results in significant toxicity. 1<~6 Although we 
did not assess vessels with specific chemical stains for 
inflammatory cells, microscopic evaluation of typical 
sections did not show evidence of gross inflammation 
or cell loss. Whether high-titer AAV vectors cause 
tissue toxicity in vivo is unknown. 
Transduction of intact arteries in vivo with use of 
adenoviral vectors results in endothelium-specific 
gene transfer, 26,27 probably because of the imperme- 
ability of the endothelium or subendothelium to 
particles the size of adenovirus (diameter ~80 
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Fig. 3. Graphs howing [3-galactosidase antigen at time intervals of 24 hours and 1 week (A) 
and J3-galactosidase activity at varying virus concentrations (B). Solid bars represent arteries 
incubated with rAAV/Col vector solution. Open bars represent paired unoperated control 
arteries. Expression is expressed as picograms (A) or microunits (B) per milligram of total 
protein in the tissue extract. Bars indicate the mean [3-galactosidase expression in each group. 
Each data point represents a single vessel. For each group in graph B, r represents he mean of 
the ratios that compare activity in the instilled versus the paired unoperated artery for each 
individual animal in that group (see text). Where p values are absent, he sample size (n) was too 
small to allow statistical analysis, iu, Infectious units. 
r im) .  28,29 In contrast, the diameter of AAV (only 
~22 nm) may allow rAAV-based vectors to penetrate 
the intact arterial wail. The mode of uptake of  
wtAAV has not been characterized, and the cellular 
receptor has not been identified. 8 Unique features of 
AAV infection may explain its apparent ability to 
transfect he media of an intact vessel after luminal 
delivery, as suggested by this study. In addition, the 
intraiuminal pressures used in this study for vector 
delivery (150 to 190 mm Hg) are similar to those 
recommended by Nabel et al. 3° for optimal in vivo 
transfer throughout an intact vessel wall with use of 
DNA-liposome complexes, which are significantly 
larger (diameter ~-250 nm) 29 than rA_A_V vectors. 
Current methods for gene transfer targeting me- 
dial cells are inefficient. 2s Gene transfer through- 
out an uninjured vessel wall would be useful for 
studying the effect of specific genes in a normal 
artery. Our study suggests that AAV vectors may 
allow direct gene transfer targeted to the medial 
smooth muscle cells, without requiring mechanical 
disruption of the intima. However, levels of  gene 
expression were very low. Recent advances in 
methods now allow production of large quantities 
of  high-titer rAAV vectors. 12,31 Transduction of  
arteries with high-titer rAAV stocks is likely to 
result in higher levels of  expression, making possi- 
ble the use ofhistochemical stains to detect recom- 
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b inant  p ro te in ,  wh ich  wil l  faci l i tate in v ivo  invest i -  
gat ions.  
Perhaps because AAV is not  cons idered to be a 
human pathogen,  basic quest ions regard ing the biol-  
ogy  o f  AAV-based  vectors remain unanswered.  Issues 
that  cou ld  be addressed in vivo inc lude ( i )  vector  
in tegrat ion  versus persistence as an episome,  (2) site 
specificity o f  integrat ion,  and (3) toxic ity o f  h igh-  
t i ter vectors.  The  potent ia l  for targeted in vivo trans- 
duct ion  o f  media l  cells in intact  arteries cou ld  be 
examined,  wi th  the u l t imate goal  o f  transferr ing a 
gene encod ing  a therapeut ic  protein.  
We thank Emily C, Huang, MD,  for technical assis- 
tance. 
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